A Phase 1 Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of BLU-554 in Patients with Hepatocellular Carcinoma and Cholangiocarcinoma

ID Number 16-0264

Principal Investigator(s)
Max W Sung

Department(s) or Division(s)
Hematology and Medical Oncology


The purpose of this study is to obtain information on the safety and tolerability of an experimental drug called BLU-554 when it is given to patients with Hepatocellular Carcinoma (HCC) and Cholangiocarcinoma.  Experimental means that it is not yet known if this drug helps patients, and it is not approved by the FDA and available for sale.  This experimental drug has not yet been tested in humans.  This is a 2-part study involving a dose-finding phase to find the most effective dose level of the study drug with the least side effects, and an expansion phase to confirm that the chosen dose of the study drug is safe and well tolerated.

Contact Information
Hoda Bashir
(212) 824-7309

Recruiting Patients: Yes